Accumulation / covering / new buying getting more aggressive..
So now we see Jazz Pharmaceuticals agreeing to buy Celator Pharmaceuticals (CPXX) in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but "no revenue" ...Hmmm, NVAX seems ripe for the picking here... The whole bio-tech sector remains in over sold territory only leads to more deal making.
Every sector over 200 day MA.... here we go
Hey Stan, any word from the BBQ pit...lol.... So in the meantime we see today Jazz Pharmaceuticals agrees to buy Celator Pharmaceuticals (CPXX) in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but no revenue...Hmmm NVAX, from a nice simmer about to go into full boil.
Accumulation continues.... Yep non event, the boogeyman at 5.80... next stop s/b 6.50 area unless of course Stan gets a bid during this weekends BBQ.....LOL...GLTA
RSV infant & older adults Ph3, Influenza Ph2 & about to head into Ph3, Pandemic in Ph2, Ebola & Matrix-M about to go into Ph2... What, what's not to like here
My immediate candidates continue to be GILD MRK & of course GSK that are now seriously looking at this baby.........Here's why kiddies: Current estimates indicate that RSV is responsible for over 30 million new acute lower respiratory infection episodes and between 150,000 and 200,000 deaths in children under five years of age . In the U.S., nearly all children become infected with RSV before they are two years of age; it has been associated with 20% of hospitalizations and 15% of office visits for acute respiratory infection in young children. In addition, it is estimated that between 11,000 to 17,000 older adults and high risk adults die of RSV infection or its complications annually in the U.S., and up to 180,000 are hospitalized for serious respiratory symptoms . The World Health Organization (“WHO”) estimates that the annual global disease burden for RSV is 64 million cases. Because there is no approved prophylactic vaccine, an RSV vaccine has the potential to protect millions of patients from this far-reaching unmet medical need.
THERE IS A SMALL GOLD MINE HERE, NOW WATCH THE PREMIUM START TO BUILD IN THIS NAME
The pause as the IBB prepares the push into the 275 - 290 trading channel...Once we get that 290 print it'll be a stones throw to assault the 200 day MA.
Exactly right, so who won't mind taking that risk reward setup.... Owning it at 3.75 is the worse case scenario
LOL... buy all you can there
Some back and fill profit taking today is par for the course, in fact some other bio's r doing the same this morning, won't last for long... As for the guy talking put options, that is laughable. Enough said
You think GSK, MRK, GILD or PFE care about converts... it'll be, for a number 5 billion dollar deal... you do the math
IBB 52 week high is 400....a 300 IBB will be easy to come by, the 200 day moving average
NVAX mgt. has an in with them.... that's all i'll say
Stan we now have Gilead Sciences holding ... They understand your busy, said they will hold all morning if necessary.... Something about having to add to their portfolio of businesses ... 14 to 18 per share, but they have room if necessary.
I am fast tracking the higher trading range to immediate....LIKE NOW
They will like to have a conversation with you....
They so silly... BTW, fast track em, FDA ALL THE WAY
Increased short at this time happens to be good for the longs... we have a rising stock price with opportunistic types like the Soros Fund and increased positions from Janus and Fidelity just to name a few. Not to mention we are finally coming up to that time where news is pending from company... GLTA